Telix Pharmaceuticals Limited

NasdaqGS:TLX Stock Report

Market Cap: US$3.4b

Telix Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Telix Pharmaceuticals has a total shareholder equity of $415.4M and total debt of $405.0M, which brings its debt-to-equity ratio to 97.5%. Its total assets and total liabilities are $1.2B and $748.6M respectively. Telix Pharmaceuticals's EBIT is $19.3M making its interest coverage ratio 2.4. It has cash and short-term investments of $141.9M.

Key information

97.51%

Debt to equity ratio

US$405.02m

Debt

Interest coverage ratio2.4x
CashUS$141.87m
EquityUS$415.38m
Total liabilitiesUS$748.61m
Total assetsUS$1.16b

Recent financial health updates

No updates

Recent updates

Seeking Alpha • May 18

Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up

Summary Telix Pharmaceuticals Limited offers a potent mix of derisking, downside cushion, and accelerating clinical/commercial momentum in the radiopharmaceutical and diagnostic space. TLX reported Q1 revenue of $230M (up 11% QoQ), reaffirmed FY26 guidance of $950M–$970M, and expects further upside from new diagnostic approvals. Strategic collaborations (notably with Regeneron) and high-profile board appointments reinforce TLX's growth trajectory and potential acquisition appeal. Pipeline progress, differentiated PSMA therapies, and patient-centric trial design position TLX for continued sales acceleration and sentiment improvement. Risks should not be ignored, including competition with peers such as Lantheus and Novartis as well as the potential for dilution to further bolster the balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Dec 26

Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO

Summary Telix Pharmaceuticals Limited, an Australian company, focuses on theranostic cancer treatments, combining diagnostics and targeted therapy, with a diverse pipeline and commercial products. Their key commercial product, Illuccix, a prostate cancer imaging agent, has generated over $600 million in U.S. sales since April 2022. TLX591, their lead therapeutic candidate for prostate cancer, shows promising efficacy but has significant side effects; other pipeline candidates are in various trial stages. Despite financial stability and scientific progress, risks include scarce data and low trading volume due to TLX being a foreign issuer. Read the full article on Seeking Alpha

Financial Position Analysis

Short Term Liabilities: TLX's short term assets ($330.3M) exceed its short term liabilities ($231.6M).

Long Term Liabilities: TLX's short term assets ($330.3M) do not cover its long term liabilities ($517.0M).

Debt to Equity History and Analysis

Debt Level: TLX's net debt to equity ratio (63.4%) is considered high.

Reducing Debt: TLX's debt to equity ratio has increased from 0.5% to 97.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if TLX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/19 06:30
End of Day Share Price 2026/06/18 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Shane StoreyCanaccord Genuity